






THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

VOLUME 35 NUMBER 3 JULY 2008



See A-2 for Figure legend

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION


The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

PM 40007777 R 9824

<https://doi.org/10.1017/S00006123080011707X> Published online by Cambridge University Press

u'ber-sharp

the power and precision of
Leksell Gamma Knife® Perfexion™



Leksell Gamma Knife® Perfexion™ and Elekta Axesse,™ an image-guided radiosurgery treatment solution optimized for neurosurgery, are redefining stereotaxy in radiation medicine. Learn more about how Elekta's new line of stereotactic radiosurgery solutions are creating new possibilities for your most challenging cases by visiting www.elekta.com/proof



Redefining Stereotaxy in Radiation Medicine *a case at a time*

THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

VOLUME 35 NUMBER 3 JULY 2008

CRITICALLY APPRAISED TOPIC SUMMARIES (CATS)

- 273 The Return of Evidence-Based Neurology to the Journal: It's All About Patient Care
ME Jenkins, JG Burneo

EDITORIAL

- 276 VNS Therapy
William Murphy

COMMENTARY

- 278 Stroke Prevention and Sodium Restriction
Norman RC Campbell, J David Spence

ORIGINAL ARTICLES

- 280 Seizure Freedom Reduces Illness Intrusiveness and Improves Quality of Life in Epilepsy
Sonia Poochikian-Sarkissian, Souraya Sidani, Richard Wennberg, Gerald M Devins
- 287 Quality of Life and Memory after Vagus Nerve Stimulator Implantation for Epilepsy
Jeannette McGlone, Ivan Valdivia, Marsha Penner, Jaime Williams, R Mark Sadler, David B Clarke
- 297 Childhood Absence Epilepsy Requiring More than One Medication for Seizure Control
B Nadler, MI Shevell
- 301 Sturge-Weber Syndrome. Study of 55 Patients
Ignacio Pascual-Castroviejo, Samuel-Ignacio Pascual-Pascual, Ramón Velazquez-Fragua, Juan Viaño
- 308 Access to Spine Care: A Tale of Two Cities
R John Hurlbert, Ralph Mobbs, Charles Teo
- 314 Can Clinical Data Predict Progression to Dementia in Amnesic Mild Cognitive Impairment?
Lesley Fellows, Howard Bergman, Christina Wolfson, Howard Chertkow
- 323 RAVLT and Nonverbal Analog: French Forms and Clinical Findings
Viviane Sziklas, Marilyn Jones-Gotman

- 331 A Novel Mutation in a Large French-Canadian Family with LGMD1B

Nicolas Chrestian, Paul N Valdmanis, Najmeddine Echahidi, Denis Brunet, Jean-Pierre Bouchard, Peter Gould, Guy A Rouleau, Jean Champagne, Nicolas Dupré

- 335 Diagnostic Accuracy of Neurological Problems in the Emergency Department

Jeremy J Moeller, Joelius Kurniawan, Gordon J Gubitza, John A Ross, Virender Bhan

- 342 The Prevalence of Cerebral Palsy in British Columbia, 1991-1995

Les Smith, Karen D Kelly, Glenda Prkachin, Donald C Voaklander

- 348 Reliability of Point-of-Care Testing of INR in Acute Stroke

Theresa L Green, Adnan Mansoor, Nancy Newcommon, Caroline Stephenson, Eileen Stewart, Michael D Hill

- 352 Restless Legs Syndrome in Patients with Chronic Obstructive Pulmonary Disease

Yuksel Kaplan, Handan Inonu, Ayse Yilmaz, Serpil Ocal

NEUROIMAGING HIGHLIGHT

- 358 *Submitted by: R Sparing, T Krings, M Dafotakis, J Noth, A Thron*

CASE REPORTS

- 360 A Case of Foreign Accent Syndrome Resulting in Regional Dialect
Raveeni Naidoo, Erin M Warriner, Wieslaw J Oczkowski, Alexandre Sévigny, Karin R Humphreys
- 366 Intravascular Lymphoma with Conus Medullaris Syndrome Followed by Encephalopathy
Martin Savard, Steve Verreault, Peter V Gould, Vincent Bernier, Jean-Pierre Bouchard

PEER REVIEWED LETTERS

- 372 A V139M Mutation Also Causes the Reversible CNS Phenotype in CMTX
Michelle Halbrich, Jeffrey Barnes, Martin Bunge, Charuta Joshi

THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

VOLUME 35 NUMBER 3 JULY 2008

375 Solitary Myofibroma of the Skull Presenting Outside Infancy

Ralph Rahme, Gerard Abadjian, Elie Samaha

378 Internal Carotid Artery Septa in Sickle Cell Disease: Risk Factor for Stroke?

Pranshu Sharma, Mayank Goyal, Ali M Al-Khathaami, Andrew Demchuk

381 Sphenoid Sinus Mucocele - Rupture Causing Brainstem Inflammation and Stroke

Kevin Busche, William F Morrish

386 The Canadian Radiosurgery Society Meeting Abstracts

Abstracts of papers and cases presented at the 3rd Meeting of the Canadian Radiosurgery Society (CaRS), Tremblant, Quebec - February 29-March 1, 2008.

397 Books Received / Books Reviewed

402 Notes and Announcements

A-9, A-10	Information for Authors
A-11	Advertisers Index
A-11, A-15	Classified Ads
A-5	CNSF Sponsors
A-8	Calendar of Events

Front Cover Figure

Intravascular Lymphoma with Conus Medullaris Syndrome Followed by Encephalopathy
Martin Savard, Steve Verreault, Peter V. Gould, Vincent Bernier, Jean-Pierre Bouchard


(A) Gross photograph of the inferior side of the brain, showing oedema of cerebral hemisphere and cerebellar congestion. (B) Large blastic lymphocytes proliferate in cerebral vessels at autopsy (H&E 20X). (C) Adrenal vessels contain the same blastic lymphocytes (CD20 40X). (D) Spinal cord vessels with the same blastic lymphocytes at high magnification (H&E 60X).

JOURNAL COVER

We are investigating different options for the cover of the Journal and thought it might be appropriate to include pictures of major Canadian Cities and/or Universities as taken by our readers.

If you are interested in submitting pictures, please send them to maggie-mccallion@cnsfederation.org in high resolution format, (i.e. tif or jpeg). Please also indicate your willingness to provide these pictures free of charge. Picture 'acknowledgement' will be provided.

The science of CT scanning is finally on the move.







The vision of the future is here. Now you can bring high-quality CT scanning directly to the bedside of your most critical patients. The CereTom® is an 8-slice portable CT scanner that provides the comparable image quality of a traditional scanner, but with a revolutionary design that gives you the freedom of portability. And the benefits are something to see...

- Quickly and easily transports wherever you need it most – the OR, the ER, or the ICU
- Keeps critical-care patients from being transported
- Capable of performing NeCT, CT Perfusion, Xenon Perfusion and CT Angiography
- Increases availability of the traditional scanner to enable a busy healthcare facility to meet its demands



For more information, call
978-564-8500
or visit us online at
www.neurologica.com

info@neurologica.com



THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

VOLUME 35 NUMBER 3 JULY 2008

Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Mandar Jog LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil Scientifique

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, ON
Robert Hammond LONDON, ON
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Douglas Kondziolka PITTSBURGH, PA, USA
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Paul Steinbok VANCOUVER, BC
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

Richard Farb TORONTO, ON
David Pelz LONDON, ON

**Neuropathological Conference/Conférence
sur la neuropathologie**

Robert Hammond LONDON, ON

Book Review/Critiques de livres

Andrew Kirk SASKATOON, SK

Critically Appraised Topic Summaries (CATS)

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

The official journal of / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie
The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie
The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique
The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:

Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situé en permanence à:
7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate for Individuals are: C\$90 (Canada), US\$90 (USA), and US\$95 (elsewhere). Subscription rates for Institutions are: C\$100 (Canada), US\$100 (USA), and US\$105 (elsewhere). Resident, intern and student rates are available. See www.cjns.org for details. Single copies C\$25 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Website: www.cjns.org COPYRIGHT © 2008 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by ASCA, ASFA, AbHyg, AgBio, BIOBASE, BIOSIS Prev, BiolAb, ChemAb, CurCont, DentInd, EMBASE, ExcerptMed, HelmAb, IABS, ISR, IndMed, Inpharma, JW-N, LHB, MEDLINE, MycolAb, NRN, NSCI, NutrAb, PE&ON, PN&I, ProtozoAb, PsycInfo, PsycholAb, RM&VM, RRTA, Reac, RefZh, SCI, SCOPUS, TDB, WeedAb, e-psyche, BLDSC (3033.300000), CASDDS, CISTI, GNLM, IDS, IE, Inforieve, Ingenta, CCC.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 90 \$C (non-membres au Canada); 90 \$É-U (Etats Unis) et 95 \$É-U (ailleurs); l'abonnement annuel pour les institutions est de 100 \$C (non-membres au Canada); 100 \$É-U (Etats Unis) et 105 \$É-U (ailleurs); Internes, résidents, fellows pré et post doctoral voir www.cjns.org pour détails. Copie simple: 25 \$C plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Website: www.cjns.org DROITS D'AUTEUR © 2008: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention: 40007777; numéro d'enregistrement PAP 09824. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans ASCA, ASFA, AbHyg, AgBio, BIOBASE, BIOSIS Prev, BiolAb, ChemAb, CurCont, DentInd, EMBASE, ExcerptMed, HelmAb, IABS, ISR, IndMed, Inpharma, JW-N, LHB, MEDLINE, MycolAb, NRN, NSCI, NutrAb, PE&ON, PN&I, ProtozoAb, PsycInfo, PsycholAb, RM&VM, RRTA, Reac, RefZh, SCI, SCOPUS, TDB, WeedAb, e-psyche, BLDSC (3033.300000), CASDDS, CISTI, GNLM, IDS, IE, Inforieve, Ingenta, CCC.

Journal Staff


Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/Production Coordinator*
Cindy Leschyshyn, *Editorial Coordinator*

Advertising representative/Représentant de publicité:

Brett Windle, *Corporate Development Coordinator*
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs. 

ISSN 0317 - 1671



The Canadian Neurological Sciences Federation is pleased to recognize our Sponsors* for 2008. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provide unrestricted educational grants to the Annual Congress, this year in Victoria, British Columbia; June 17th – 20, 2008.

Diamond



Platinum



Gold



Silver



Bronze

Talecris Biotherapeutics

Neurological Sciences
Foundation of Canada

Canadian Neurological Society
Foundation

Supporters

Lundbeck Canada
Stellate
Allergan

Codman Neuro/Johnson & Johnson
Roxon Medi-Tech
Teva Neuroscience
Boehringer/Lilly

IMRIS
Neurologica
Bayer Healthcare

Treat your hypertensive patients with the power of MICARDIS.:

- ▲ Powerful 24-hour BP reductions shown, $p < 0.0001$ including the early morning hours (6:00 AM–11:59 AM), $p < 0.0001$ ^{2†}
- ▲ Longest half-life of all AT₁ receptor blockers^{3-8§}
- ▲ Simple, flexible, once-daily dosing^{3*}

ONTARGET

▲ The ONTARGET clinical trial program investigates ARB and ACE therapy in more than 31,000 patients.

- ▲ ONTARGET investigates MICARDIS (telmisartan) and ramipril alone or in combination, in the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications.
- ▲ Boehringer Ingelheim is committed to cardiovascular protection research.

MICARDIS is not indicated to reduce cardiovascular or cerebrovascular morbidity and mortality, or to improve renal outcomes.

MICARDIS
 TELMISARTAN 80mg AT₁ RECEPTOR BLOCKER
 GOOD MORNING. MICARDIS.



Boehringer
 Ingelheim

COMMITTED TO CARDIOVASCULAR
 PROTECTION RESEARCH
 www.boehringer-ingelheim.com



MICARDIS. Demonstrated Powerful BP Reductions Measured from MORNING to MORNING¹



Demonstrated significantly greater 24-hour ABPM reduction vs. placebo, $p < 0.05$ [#]

MICARDIS (telmisartan) is indicated for the treatment of mild to moderate essential hypertension and may be used alone or in combination with thiazide diuretics.³ The most common adverse events vs. placebo were headache (8.0% vs. 15.6%), upper respiratory tract infection (6.5% vs. 4.6%), dizziness (3.6% vs. 4.6%), pain (3.5% vs. 4.3%), fatigue (3.2% vs. 3.3%), back pain (2.7% vs. 0.9%), diarrhea (2.6% vs. 1.0%) and sinusitis (2.2% vs. 1.9%).³ If pregnancy is detected, MICARDIS should be discontinued as soon as possible.³ In patients who are volume-depleted by diuretic therapy, dietary salt restrictions, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS.³

[#] 6-week, multinational, multicentre, randomized, double-blind, double-dummy, parallel group study comparing MICARDIS 80 mg and losartan 50 mg with placebo arm. MICARDIS 80 mg mean 24-hour SBP vs. placebo = -13.3 mmHg vs. -1.8 mmHg, DBP = -8.4 mmHg vs. -0.8 mmHg, $p < 0.05$.

[†] 14-week, multicentre, prospective, randomized, open-label, blinded-endpoint, parallel group, forced-titration study of MICARDIS and Altace[®] in patients with confirmed ambulatory hypertension. Mean 24-hour SBP = -14.8 mmHg vs. -10.7 mmHg, $p < 0.0001$ and DBP = -9.9 mmHg vs. -6.7 mmHg, $p < 0.0001$. Morning (06:00 AM–11:59 AM) SBP = -14.5 mmHg vs. -9.7 mmHg, $p < 0.0001$.

[§] Comparative clinical significance is unknown.

^{*} Dosing available in MICARDIS 40 mg, MICARDIS 80 mg and MICARDIS PLUS 80/17.5 mg HCTZ.

MICARDIS is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.

Boehringer Ingelheim: Committed to cardio and vascular protection research

>31,000
patients enrolled
in the **ONTARGET**
two-part study
programme^{1,2}

MICARDIS® (telmisartan) is indicated for the treatment of mild to moderate essential hypertension and may be used alone or in combination with thiazide diuretics.

The most common adverse events vs. placebo were headache (8.0% vs. 15.6%), upper respiratory tract infection (6.5% vs. 4.6%), dizziness (3.6% vs. 4.6%), pain (3.5% vs. 4.3%), fatigue (3.2% vs. 3.3%), back pain (2.7% vs. 0.9%), diarrhea (2.6% vs. 1.0%) and sinusitis (2.2% vs. 1.9%).

If pregnancy is detected, MICARDIS® should be discontinued as soon as possible. In patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS®.

MICARDIS® is not indicated to reduce cardiovascular or cerebrovascular morbidity and mortality, or to improve renal outcomes.

1. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. *American Heart Journal* 2004;148 vol.1:52-61. 2. Data on file, Boehringer Ingelheim (Canada) Ltd.

MICARDIS® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. PRoFESS® is a registered trademark used under license by Boehringer Ingelheim GmbH, Germany. Aggrenox® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. Altace® is a registered trademark of sanofi-aventis Canada. Plavix® is a registered trademark of sanofi-aventis Canada.



Current Ongoing International Cardio and Vascular Trials:

	ONTARGET	TRANSCEND	PRoFESS®
Number of Patients Internationally	25,622 ²	5,926 ²	20,333 ²
Number of Canadian Patients	2,519 ²	426 ²	1,549 ²
Number of International Centres	730 ^{1,2}	730 ^{1,2}	674 ²

ONTARGET Cardiovascular Mortality and Morbidity Trial

- ▶ ONTARGET investigates MICARDIS® (telmisartan) and Altace® (ramipril), alone or in combination, in the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications.¹
- ▶ Inclusion Criteria:¹
 - ▶ Male or female, age ≥55 years
 - ▶ At high risk of developing a CVD event, with a history of one of the following:
 - Coronary artery disease
 - Peripheral arterial occlusive disease (PAOD)
 - Cerebrovascular event
 - Diabetes mellitus with evidence of end-organ disease

TRANSCEND Cardiovascular Mortality and Morbidity Trial

- ▶ TRANSCEND investigates MICARDIS® vs. placebo for the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications and who are intolerant to angiotensin-converting enzyme inhibitors.¹

PRoFESS® Stroke Trial

- ▶ PRoFESS® investigates patients with known prior ischemic strokes. Patients will receive at random either MICARDIS® or placebo. Both groups will also receive at random either Aggrenox® (ASA/extended-release dipyridamole) or Plavix® (clopidogrel).²

COMMITTED TO CARDIO AND
VASCULAR PROTECTION RESEARCH



Boehringer
Ingelheim

www.boehringer-ingelheim.ca

CALENDAR OF EVENTS

July 3-4, 2008

Utrecht, Netherlands

Brain-Computer Interfacing in 2008. A Symposium on the Cutting Edge of Applied Neuroscience

Anyone interested in: Human Brain Function, Interfacing with the human brain and mind, Developing solutions for paralyzed patients visit www.bci2008.nl for more information.

July 23-25, 2008

Chicago, Illinois, USA

ACI's 12th National Conference on Neuroscience Centers of Excellence

To register contact: Dan Can Stedum at Phone: (312) 780-0700 Ext. 114, Fax: (312) 780-0600 or Email: dvanstedum@aci.us.net.

July 31-August 1, 2008

Boston, Massachusetts, USA

Sporadic Neurodegeneration: Genes, Environment and Therapeutic Strategies

For more information or to register go to: <http://www.biosymposia.org/content26843.html>.

September 5-6, 2008

Toronto, Ontario, Canada

9th Annual Interventional Neuroradiology Symposium

For more information contact the Office of Continuing Education and Professional Development, E-mail: help-MIM0804@cmeteronto.ca or go to our website: www.cme.utoronto.ca

September 17-20, 2008

Montreal, Quebec, Canada

World Congress on Treatment and Research in Multiple Sclerosis

Please visit www.msmontrreal for more information on program, registration and abstract submission.

September 24-27, 2008

5th World Congress for NeuroRehabilitation in Conjunction with the World Federation of NeuroRehabilitation (WFNR)

For more information go to www.sarah.br/wfnr-rio2008.

October 5-7, 2008

Vancouver, British Columbia, Canada

7th North American Conference on Shaken Baby Syndrome (Abusive Head Trauma)

For information go to: www.dontshake.org

October 23-26, 2008

Athens, Greece

Controversies in Neurology (CONy)

For additional information regarding CONy, please visit our website: www.comtecmed.com/cony

October 24, 2008 (Part I)

November 7-9, 2008 (Part II)

Calgary, Alberta, Canada

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Program

For further information or to register, please visit www.cme.ucalgary.ca

November 9-11, 2008

Houston, Texas, USA

Goodman Oral Board Preparation: Neurosurgery Review by Case Management

For more information or to register, please visit www.AANS.org or email epm@aans.org

November 13-15, 2008

Sicily, Italy

European Charcot Foundation Symposium 2008. Multiple Sclerosis and Gender

Programme and more information available via www.charcot-ms.eu.

January 16-18, 2009

Orlando, Florida, USA

AAN Annual Meeting

For information go to: www.aan.com/fall07

April 15-18, 2009

Rotterdam, The Netherlands

9th European Skull Base Society Meeting

For more information, please visit our website at: www.esbs2009.eu.

April 25-28, 2009

Rome, Italy

XI International Facial Nerve Symposium

For more information go to www.facialnerve2009.org.

June 9-12, 2009

Halifax, Nova Scotia, Canada

44th Annual Congress of the Canadian Neurological Sciences Federation

For more information go to: www.cnsfederation.org or contact the secretariat office at (403) 229-9544.

August 30-September 4, 2009

Boston, Massachusetts, USA

XIV Congress of the World Federation of Neurosurgical Societies (WFNS)

For more information or to register, please visit www.AANS.org/wfns2009 or email wfns2009@aans.org